Posts

AstraZeneca reportedly cuts about 600 U.S. commercial roles

Bloomberg reported on Nov. 13 that AstraZeneca cut about 600 roles across its U.S. respiratory and immunology commercial teams. Some affected staff were reportedly involved in marketing the asthma medicines Breztri and Airsupra. Some employees may be reassigned to other roles; the number who will leave the company is unclear. The cuts are part of a three-year plan targeting about $1.5 billion in annual savings, with the savings intended to support investment in AstraZeneca’s drug pipeline. The plan may involve up to $2 billion in one-time restructuring costs. AstraZeneca declined to comment on the reported job cuts. The company has said the broader restructuring is not expected to reduce its overall workforce. Sources: AstraZeneca Cuts 600 US Sales Staff as Savings Drive Kicks In AstraZeneca cuts 600 sales jobs in US, Bloomberg News ... AstraZeneca cuts 600 sales jobs in US, Bloomberg News reports AstraZeneca Cuts US Commercial Workforce as Part of USD 1.5 Billion Annua...

Lilly to acquire Calytrix Bio for up to $1.5 billion

FDA blocks ivonescimab’s near-term US launch over survival-data concerns

LEO Pharma delays IPO plans beyond 2026

Seawolf launches with $100M to develop non-viral DNA therapies

Milestone plans 20% workforce cut as CFO and CMO depart

FDA rejects ivonescimab for a narrow lung cancer indication

QRL-201 FDA IND clearance: headline not confirmed by available results

HHS backs ibogaine development and broader psychedelic research

Regeneron’s baloncibart shows Phase 2 promise in POTS

Windward raises $225M with Sanofi support as Rezera postpones IPO

Bavarian Nordic beats Q3 revenue estimates as CFO announces planned 2027 departure

FDA’s speedy voucher program reportedly shelved, but HHS says pilot is ongoing